Pembrolizumab (anti-PD-1)  (Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1))

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1^[1][2].

去铁胺 (Df) 螯合 Pembrolizumab，不会阻碍或改变 Pembrolizumab 与 CD4+ 和 CD8+ T 细胞的结合亲和力或特异性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

实验证实，⁸⁹Zr-Df-Pembrolizumab 具有 740 mBq/mg 抗体的特异性活性。其中，mBq 是放射性活度的单位，用于衡量放射性衰变^[2]。
正电子发射体 ⁸⁹Zr 标记的去铁胺 (Df)-Pembrolizumab，经过 PET 成像，能够动态追踪其生物分布。结果显示，Pembrolizumab 在血液循环中保持稳定，并在肝和脾组织中积累最多。且在小鼠和大鼠均表现出相似的生物分布和药代动力学^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

液体

Colorless to light yellow

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.  [Content Brief]

  [2]. England CG, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168.  [Content Brief]